Skip to main content

Table 5 Lab values

From: A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss

Variable LLLT (N = 15) Lorcaserin (N = 14) Combination (N = 13a)
Hgb_a1c
 Baseline 5.59 ± 0.92 5.31 ± 0.51 5.36 ± 0.23
 Week 12 5.71 ± 1.12 5.29 ± 0.43 5.33 ± 0.30
 Delta +0.12 ± 0.29 −0.02 ± 0.14 −0.03 ± 0.13
CRP
 Baseline 4.72 ± 3.22 4.71 ± 3.62 4.60 ± 2.18
 Week 12 4.81 ± 2.79 4.04 ± 2.55 5.97 ± 5.69
 Delta +0.09 ± 1.86 −0.68 ± 1.40 +1.37 ± 5.61
LDL
 Baseline 111.3 ± 28.7 95.1 ± 19.0 117.5 ± 31.0
 Week 12 115.1 ± 29.4 94.9 ± 20.8 107.0 ± 28.8
 Delta +3.8 ± 22.2 −0.3 ± 17.8 −10.5 ± 22.2
Non-HDL Cholesterol
 Baseline 137.5 ± 33.0 128.4 ± 27.2 141.8 ± 34.7
 Week 12 139.5 ± 37.3 121.6 ± 30.7 128.7 ± 33.7
 Delta +2.0 ± 24.6 −6.8 ± 18.8 −13.1 ± 24.2
HDL
 Baseline 62.3 ± 14.5 53.6 ± 14.5 60.3 ± 16.7
 Week 12 61.5 ± 17.5 51.3 ± 12.7 56.5 ± 15.7
 Delta −0.8 ± 7.5 −2.3 ± 7.1 −3.8 ± 7.7
Triglycerides
 Baseline 130.7 ± 48.7 166.1 ± 98.5 119.8 ± 51.5
 Week 12 121.9 ± 62.3 134.1 ± 85.3 108.7 ± 50.1
 Delta −8.9 ± 39.7 −32.1 ± 39.0** −11.2 ± 56.2
Total Cholesterol
 Baseline 199.8 ± 29.0 182.0 ± 26.7 202.1 ± 27.3
 Week 12 201.0 ± 35.7 172.9 ± 30.8 185.2 ± 33.0
 Delta +1.2 ± 30.1 −9.1 ± 23.5 −16.8 ± 24.2*
Fasting Glucose
 Baseline 89.7 ± 11.7 90.6 ± 14.6 88.6 ± 13.6
 Week 12 92.5 ± 20.1 60.2 ± 17.8 87.7 ± 8.7
 Delta +2.8 ± 10.9 −0.4 ± 7.0 −0.9 ± 8.1
Leptin
 Baseline 38.1 ± 15.7 35.7 ± 21.2 37.2 ± 26.0
 Week 12 34.0 ± 12.4 34.1 ± 23.6 30.8 ± 21.4
 Delta −4.1 ± 11.6 −1.6 ± 11.3 −6.4 ± 12.1
Adiponectin
 Baseline 9,719 ± 5,534 7,955 ± 3,463 12,412 ± 8,393
 Week 12 8,987 ± 4,050 7,156 ± 2,231 12,254 ± 7,273
 Delta −732 ± 3,970 −799 ± 2,237 −158 ± 2,787
  1. * p < 0.05, ** p < 0.01for paired t-test comparing week 12 versus baseline
  2. aOf the 15 subjects assigned to the combination group, 2 discontinued prior to week 12 and are not included in the analysis